AtriCure, Inc.
For the period ended Dec 31, 2025. Filed Feb 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 19, 2026
ATRC$56.26-2.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2025, 2024 and 2023
(In Thousands)
| 2025 · 2024 · 2023 | |||||
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net loss | $(11,448) | $(44,698) | $(30,438) | ||
| Adjustments to reconcile net loss to net cash provided by operating activities: | |||||
| Share-based compensation expense | 44,685 | 40,405 | 35,728 | ||
| Depreciation | 12,090 | 11,214 | 9,460 | ||
| Amortization of intangible assets | 8,441 | 7,519 | 5,353 | ||
| Amortization of deferred financing costs | 478 | 478 | 486 | ||
| Amortization of investments | — | 107 | 632 | ||
| Acquired in-process research and development expense | 6,000 | 12,000 | — | ||
| Loss on debt extinguishment | — | 1,362 | — | ||
| Other non-cash adjustments | 1,374 | 2,175 | 1,503 | ||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable | (5,610) | (8,301) | (9,872) | ||
| Inventories | (2,256) | (7,740) | (21,830) | ||
| Other current assets | (328) | (949) | (3,084) | ||
| Accounts payable | (960) | (1,531) | 6,177 | ||
| Accrued liabilities | 6,997 | 1,199 | 11,562 | ||
| Other noncurrent assets and liabilities | (2,129) | (1,036) | (1,193) | ||
| Net cash provided by operating activities | 57,334 | 12,204 | 4,484 | ||
| Cash flows from investing activities: | |||||
| Sales and maturities of available-for-sale securities | — | 53,668 | 63,815 | ||
| Purchases of property and equipment | (9,050) | (11,459) | (11,998) | ||
| Proceeds from sale of property and equipment | — | 25 | — | ||
| Acquisitions, including in-process research and development | (6,000) | (12,000) | (30,000) | ||
| Proceeds from capital grant | 500 | — | — | ||
| Net cash (used in) provided by investing activities | (14,550) | 30,234 | 21,817 | ||
| Cash flows from financing activities: | |||||
| Proceeds from revolving credit facility, net of financing costs | — | 61,210 | — | ||
| Payments on debt, leases and financing obligation | (1,201) | (62,879) | (992) | ||
| Proceeds from financing obligation | 6,250 | — | — | ||
| Payment of financing costs and bank fees | — | (1,069) | (60) | ||
| Proceeds from stock option exercises | 1,367 | 1,022 | 2,316 | ||
| Shares repurchased for payment of taxes on stock awards | (11,163) | (6,951) | (6,557) | ||
| Proceeds from issuance of common stock under employee stock purchase plan | 5,923 | 5,064 | 5,261 | ||
| Net cash provided by (used in) financing activities | 1,176 | (3,603) | (32) | ||
| Effect of exchange rate changes on cash and cash equivalents | 747 | (424) | (58) | ||
| Net increase in cash and cash equivalents | 44,707 | 38,411 | 26,211 | ||
| Cash and cash equivalents—beginning of period | 122,721 | 84,310 | 58,099 | ||
| Cash and cash equivalents—end of period | $167,428 | $122,721 | $84,310 | ||
| Supplemental cash flow information: | |||||
| Cash paid for interest | $5,255 | $5,951 | $6,376 | ||
| Cash paid for income taxes, net of refunds | 1,290 | 619 | 395 | ||
| Non-cash investing and financing activities: | |||||
| Accrued purchases of property and equipment | 1,262 | 334 | 1,427 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.